000043653 001__ 43653 000043653 005__ 20240822130611.0 000043653 0247_ $$2doi$$a10.6083/bpxhc43653 000043653 037__ $$aIR 000043653 041__ $$aeng 000043653 245__ $$aComputational assessment of T cell plasticity in immune related adverse events 000043653 260__ $$bOregon Health and Science University 000043653 269__ $$a2024 000043653 336__ $$aAbstract 000043653 520__ $$aImmune checkpoint blockade (ICB) therapy targets checkpoint proteins to restore normal function to the immune system so that it can attack cancer cells. It is used successfully to treat a variety of cancers; however, many patients suffer from the development of immune-related adverse events (irAEs), which may affect any organ system and can be severe enough to cause the cessation of therapy. There is therefore great interest in understanding the mechanism of irAE development. Our work contributes to the understanding of the role of Treg plasticity and Treg-Th17 balance in the context of ICB treatment and irAE development that will guide future research in the field. 000043653 540__ $$fCC BY 000043653 542__ $$fIn copyright - joint owners 000043653 650__ $$aImmune Checkpoint Inhibitors$$013296 000043653 650__ $$aCell Plasticity$$011081 000043653 650__ $$aSequence Analysis, RNA$$029959 000043653 6531_ $$aimmune related adverse events (irAEs) 000043653 6531_ $$aimmune checkpoint blockade (ICB) 000043653 6531_ $$aT cells 000043653 6531_ $$aT cell plasticity 000043653 6531_ $$asingle cell RNA sequencing 000043653 691__ $$aSchool of Medicine$$041369 000043653 692__ $$aDepartment of Dermatology$$041406 000043653 7001_ $$aFey, Rosalyn M.$$uOregon Health and Science University$$041354 000043653 7001_ $$aKulkarni, Rajan P.$$uOregon Health and Science University$$041354 000043653 711__ $$aResearch Week$$uOregon Health and Science University$$d2024 000043653 8564_ $$922827f26-903b-41c8-9171-08ac13c9aacc$$s185013$$uhttps://digitalcollections.ohsu.edu/record/43653/files/ResearchWeek.2024.Fey.Rosalyn.pdf 000043653 980__ $$aResearch Week